NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a
tech-enabled drug development partner committed to improving the
speed, quality, and innovation of clinical trials, today announced
a collaboration with resTORbio, Inc. (Nasdaq: TORC). resTORbio is a
clinical-stage biotechnology company developing innovative
medicines that target the biology of aging to treat aging-related
diseases.
resTORbio is the recipient of an NIA grant to investigate
RTB-101 against COVID-19 outside the hospital in a community study.
Previous RTB-101 clinical studies in similar patient populations
have offered encouraging respiratory function efficacy data with a
clean safety profile, offering a promising option for patients. The
study will assess RTB-101's efficacy in preventing symptom
development and downstream hospitalizations among positive,
asymptomatic patients as well as any cohabitants of patients
diagnosed with COVID-19.
"We've been encouraged by initial results for drugs in the
hospitalized, inpatient setting, but there is still a great need
for products to reduce the burden of disease in the community,"
said Joan Mannick, MD, Chief Medical
Officer at resTORbio. "TrialSpark's Project Covalence platform will
allow us to rapidly initiate our study while limiting the potential
exposure for patients while they are sheltering in place. Further,
TrialSpark's end-to-end technology stack, which seamlessly
integrates eConsent, eSource, EDC, Payments, and ePRO replaces
several point solutions that we had utilized previously."
TrialSpark's Project Covalence platform, which launched on
June 16, is a collaboration between
TrialSpark, Sam Altman, and Dr.
Mark Fishman. The platform was
designed with programs like resTORbio's RTB-101 study in mind,
where researchers and pharma companies could easily, and rapidly,
test repurposed medications with promising hypotheses and signals
against COVID-19 in the community setting.
"Launching trials in the midst of COVID-19 is uniquely
challenging given the many logistical and operational challenges.
Because our trial platform supports in-person, remote, at-home, and
hybrid visits, we empower our biotech partners to ensure patient
and trial continuity in this uncertain environment. We're thrilled
to support biotechs like resTORbio in the fight against COVID-19.
Our team is excited about the opportunity to accelerate the
development of new drugs and vaccines for COVID-19 by streamlining
the clinical trial process." said Ben
Liu, Chief Executive Officer of TrialSpark.
The Project Covalence platform is designed to run multiple
studies to validate new diagnostics, treatments, and vaccines. This
is the second study being launched on the platform and we look
forward to announcing others in the coming weeks and months.
About TrialSpark
TrialSpark is a technology company that runs end-to-end clinical
trials as an alternative to a traditional CRO. TrialSpark partners
with doctors to create trial sites within their existing practices
and runs trials out of these sites using a roaming cohort of
research coordinators, optimized by software, data, and technology.
By creating trial sites with doctors, TrialSpark unlocks the 99% of
patients who traditionally haven't been able to participate in
trials, boosting recruitment rates and democratizing access.
TrialSpark is backed by leading investors such as Michael Moritz, John
Doerr, Thrive Capital, and Sequoia Capital.
For more information, please visit
www.trialspark.com/sponsors.
About Project Covalence
Project Covalence provides the technology, clinical operations,
and logistical support needed to launch and run COVID-19 clinical
trials. In particular, the Project Covalence platform is optimized
for community-based studies centered at the patient home or
outpatient trial sites, reducing the burden on hospitals and health
systems while democratizing access to research. Private and public
researchers can leverage Project Covalence's shared infrastructure
to rapidly launch their clinical trials using a wide array of
capabilities like 21 CFR Part 11 compliant remote data collection,
telemedicine, at-home testing and specimen collection, protocol
design and writing, digital patient recruitment, and other needs
during this unique time. For more information, please visit
projectcovalence.com or contact one of our team members
at https://projectcovalence.com/get-involved.
CONTACT: press@trialspark.com
View original
content:http://www.prnewswire.com/news-releases/restorbio-and-trialspark-collaborate-to-investigate-rtb-101-for-covid-19-on-the-project-covalence-platform-301100964.html
SOURCE TrialSpark